Medicenna Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
2026
Medicenna Therapeutics Stock-Based Compensation Growth & History (MDNAF)
Medicenna Therapeutics's stock-based compensation was $1.6M for fiscal 2026.
View full Medicenna Therapeutics company overviewMedicenna Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $1.6M | −$625,000 | −28.23% |
| 2025 | 2025-03-31 | $2.2M | $1.0M | +83.13% |
| 2024 | 2024-03-31 | $1.2M | −$162,000 | −11.82% |
| 2023 | 2023-03-31 | $1.4M | −$44,000 | −3.11% |
| 2022 | 2022-03-31 | $1.4M | $409,000 | +40.66% |
| 2021 | 2021-03-31 | $1.0M | −$119,000 | −10.58% |
| 2020 | 2020-03-31 | $1.1M | — | — |
Medicenna Therapeutics quarterly stock-based compensation
Q4.21
Q4.22
Q4.23
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | $327,000 | −$63,000 | −16.15% |
| Q4 2026 | 2026-03-31 | $400,000 | −$96,000 | −19.35% |
| Q3 2026 | 2025-12-31 | $331,000 | — | — |
| Q2 2026 | 2025-09-30 | $468,000 | — | — |
| Q1 2026 | 2025-06-30 | $390,000 | — | — |
| Q4 2025 | 2025-03-31 | $496,000 | — | — |
| Q4 2023 | 2023-03-31 | $1.4M | −$44,000 | −3.11% |
| Q4 2022 | 2022-03-31 | $1.4M | $409,000 | +40.66% |
| Q4 2021 | 2021-03-31 | $1.0M | — | — |
Medicenna Therapeutics stock-based compensation trends
Over the last five fiscal years, Medicenna Therapeutics's stock-based compensation increased from $1.0M to $1.6M, a change of $583,000. The latest reported quarter, Q1 2027, shows $327,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Medicenna Therapeutics source filings ↗